Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Alok Chandra, Ravi Kanth, Sandeep Thareja Department of Gastroenterology, Base Hospital, New Delhi, IndiaCorrespondence: Ravi KanthDepartment of Gastroenterology, Base Hospital, New Delhi, IndiaEmail ravikanthf2@gmail.comBackground: Adalimumab (ADA) is approved for the management of lcerative coliti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chandra A, Kanth R, Thareja S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
ulcerative colitis
steroid refractory
adalimumab
biosimilar
exemptia
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/4ee0ed2fcfae45939725130e128f6ee8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares